# Filippo Petti

> Filippo Petti is the Chief Executive Officer of Leucid Bio, a London-based clinical-stage biotech developing next-generation CAR-T cell therapies for solid tumours built on a proprietary lateral CAR platform spun out of two decades of King's College London research. Appointed CEO in July 2023, Petti pairs a bench-science start at OSI Pharmaceuticals with years on Wall Street as a healthcare investment banker and equity analyst, and a prior run leading Celyad Oncology as CEO and CFO. Under his watch, Leucid moved its lead asset LEU011 into the AERIAL Phase I/IIa trial, reporting early proof-of-concept in relapsed/refractory solid tumours in late 2025.

- **Role:** Chief Executive Officer at Leucid Bio
- **Organizations:** Leucid Bio, Celyad Oncology SA, Wells Fargo Securities, William Blair & Company, Wedbush Securities, OSI Pharmaceuticals
- **Nationality:** American
- **Education:** Master of Business Administration (MBA), Cornell University, Master of Science (MS), St. John's University, Bachelor of Science (BS), Syracuse University
- **Known for:** Appointed CEO of Leucid Bio in July 2023, joining the board of directors, Advanced Leucid's lead asset LEU011 into the AERIAL Phase I/IIa clinical trial for solid tumours, Reported early proof-of-concept data for a lateral CAR-T in relapsed/refractory solid tumours in late 2025

## Career timeline

- **early career** — Research scientist at OSI Pharmaceuticals focused on drug discovery and translational research, later moving into corporate development
- **2000s-2010s** — Equity research analyst covering US biotechnology at William Blair & Company and Wedbush Securities
- **2010s** — Healthcare investment banker at Wells Fargo Securities and William Blair & Company, specializing in cell and gene therapy companies
- **2018-2023** — CEO, CFO and Executive Director of Celyad Oncology SA, a CAR-T cell therapy company
- **2023** — Appointed Chief Executive Officer and board member of Leucid Bio (July 2023)
- **2025** — Leucid Bio reports early proof-of-concept for LEU011 in the AERIAL Phase I/IIa solid tumour trial

## Achievements

- Appointed CEO of Leucid Bio in July 2023, joining the board of directors
- Advanced Leucid's lead asset LEU011 into the AERIAL Phase I/IIa clinical trial for solid tumours
- Reported early proof-of-concept data for a lateral CAR-T in relapsed/refractory solid tumours in late 2025
- Previously led Celyad Oncology as both CEO and CFO
- Built a rare career spanning laboratory research, equity research, investment banking and executive leadership in cell therapy

## Latest updates

- **2025-11** — Leucid Bio presented AERIAL trial data at the SITC Annual Meeting establishing early proof-of-concept for LEU011 in solid tumours, with additional data anticipated in the first half of 2026.
- **2025-09** — Petti appeared in a fireside chat discussing Leucid's lateral CAR platform and clinical progress.

## Links

- Website: https://leucid.com
- LinkedIn: https://www.linkedin.com/in/fpetti/

---

Profile page: https://yespress.io/filippo-petti
Published by YesPress — https://yespress.io
Last updated: 2026-07-17